Jurkat-76, a TCR α/β-negative sub-line of Jurkat (CD8− T lymphoma cell line) was thought to be an ideal candidate as a source of the platform cell line because it could not produce endogenous TCRs and thus because transduced TCRs would be well expressed without competition with endogenous TCRs. Here, CD8A is linked to lymphoma.